Gateway Wealth Partners LLC Invests $493,000 in Quest Diagnostics Incorporated $DGX

Gateway Wealth Partners LLC acquired a new position in Quest Diagnostics Incorporated (NYSE:DGX) during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 2,516 shares of the medical research company’s stock, valued at approximately $493,000.

Several other large investors also recently added to or reduced their stakes in DGX. Moneta Group Investment Advisors LLC grew its position in Quest Diagnostics by 3.7% during the fourth quarter. Moneta Group Investment Advisors LLC now owns 1,387 shares of the medical research company’s stock worth $241,000 after buying an additional 50 shares in the last quarter. HB Wealth Management LLC increased its stake in Quest Diagnostics by 0.5% in the 4th quarter. HB Wealth Management LLC now owns 11,292 shares of the medical research company’s stock worth $1,960,000 after acquiring an additional 58 shares during the last quarter. Ossiam raised its holdings in shares of Quest Diagnostics by 6.1% in the 3rd quarter. Ossiam now owns 1,059 shares of the medical research company’s stock valued at $202,000 after acquiring an additional 61 shares in the last quarter. Independent Advisor Alliance boosted its position in shares of Quest Diagnostics by 1.6% during the 4th quarter. Independent Advisor Alliance now owns 4,298 shares of the medical research company’s stock valued at $746,000 after acquiring an additional 66 shares during the last quarter. Finally, Checchi Capital Advisers LLC boosted its position in shares of Quest Diagnostics by 5.6% during the 4th quarter. Checchi Capital Advisers LLC now owns 1,326 shares of the medical research company’s stock valued at $230,000 after acquiring an additional 70 shares during the last quarter. Institutional investors own 88.06% of the company’s stock.

Quest Diagnostics Price Performance

Shares of Quest Diagnostics stock opened at $233.21 on Friday. The company has a current ratio of 1.59, a quick ratio of 1.46 and a debt-to-equity ratio of 0.72. The firm has a market capitalization of $25.74 billion, a PE ratio of 24.76, a price-to-earnings-growth ratio of 2.16 and a beta of 0.58. The business’s 50-day moving average price is $207.36 and its 200-day moving average price is $199.58. Quest Diagnostics Incorporated has a 12 month low of $166.76 and a 12 month high of $240.13.

Quest Diagnostics (NYSE:DGX) last announced its quarterly earnings data on Thursday, July 23rd. The medical research company reported $3.12 earnings per share for the quarter, beating analysts’ consensus estimates of $2.82 by $0.30. The company had revenue of $3.04 billion for the quarter, compared to analysts’ expectations of $2.97 billion. Quest Diagnostics had a return on equity of 16.01% and a net margin of 9.18%.Quest Diagnostics’s revenue for the quarter was up 10.2% compared to the same quarter last year. During the same period last year, the firm posted $2.62 EPS. Quest Diagnostics has set its FY 2026 guidance at 11.050-11.250 EPS. Sell-side analysts forecast that Quest Diagnostics Incorporated will post 11.15 EPS for the current fiscal year.

Quest Diagnostics Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Wednesday, July 22nd. Shareholders of record on Wednesday, July 8th were paid a dividend of $0.86 per share. The ex-dividend date of this dividend was Wednesday, July 8th. This represents a $3.44 annualized dividend and a dividend yield of 1.5%. Quest Diagnostics’s dividend payout ratio (DPR) is 36.52%.

Insider Transactions at Quest Diagnostics

In related news, SVP Mark E. Delaney sold 1,600 shares of the stock in a transaction on Tuesday, July 28th. The shares were sold at an average price of $235.18, for a total transaction of $376,288.00. Following the transaction, the senior vice president owned 10,335 shares of the company’s stock, valued at approximately $2,430,585.30. This trade represents a 13.41% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Karthik Kuppusamy sold 8,147 shares of Quest Diagnostics stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $200.00, for a total transaction of $1,629,400.00. Following the completion of the transaction, the senior vice president owned 13,510 shares in the company, valued at approximately $2,702,000. The trade was a 37.62% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 19,747 shares of company stock worth $3,947,088. 0.88% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on DGX shares. Truist Financial boosted their price objective on Quest Diagnostics from $225.00 to $250.00 and gave the stock a “hold” rating in a report on Friday, July 24th. Jefferies Financial Group reiterated a “buy” rating and set a $245.00 target price on shares of Quest Diagnostics in a research report on Thursday, July 23rd. Robert W. Baird boosted their price target on shares of Quest Diagnostics from $236.00 to $255.00 and gave the stock a “neutral” rating in a research note on Friday, July 24th. Wall Street Zen raised shares of Quest Diagnostics from a “hold” rating to a “buy” rating in a report on Tuesday. Finally, Barclays raised their price objective on shares of Quest Diagnostics from $230.00 to $250.00 and gave the company an “overweight” rating in a research report on Thursday, July 23rd. Six analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the company. According to data from MarketBeat, the company has an average rating of “Hold” and an average price target of $235.31.

About Quest Diagnostics

Quest Diagnostics (NYSE: DGX) is a leading provider of diagnostic information services that supports clinical decision-making for patients, physicians and healthcare organizations. The company operates a network of clinical laboratories and patient service centers that perform a broad range of laboratory tests and diagnostic assays used in routine care, disease diagnosis, monitoring and screening.

Its services span core clinical laboratory testing, anatomic pathology, molecular and genomic diagnostics, infectious disease testing and toxicology.